Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 04:00 ET | Source: Epitopea

Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer

CAMBRIDGE, Royaume-Uni et MONTRÉAL, 13 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique spécialisée dans l'immunothérapie contre le cancer qui développe des immunothérapies à...
April 13, 2026 04:00 ET | Source: Epitopea

Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield

CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies...
April 13, 2026 03:51 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows

LENZELTA® is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers1. Administration is simple with two doses during the dry-off...
April 13, 2026 02:00 ET | Source: SynOx Therapeutics Limited

SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)

TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically...
April 13, 2026 01:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly...
April 13, 2026 01:00 ET | Source: BioVersys

Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)

BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and...
April 12, 2026 16:56 ET | Source: Coalition of Asia Pacific Tobacco Harm Reduction Advocates

Scrap the Ban, Keep the Controls: CAPHRA's Message to Bangladesh

CAPHRA supports Bangladesh’s review of its sweeping 2025 ban on vaping and other emerging nicotine products as a chance to save lives.
April 11, 2026 10:00 ET | Source: Klaiyi Hair

Upcoming National Women’s Health Week: Promoting Scalp Care and Breathable Wig Solutions

To support women on their health journey, Klaiyi Hair offers skin-friendly wigs designed to protect and nourish the scalp while offering versatile styling.
April 10, 2026 17:02 ET | Source: Replimune, Inc.

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
April 10, 2026 16:09 ET | Source: Mesoblast Limited

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10,...